• Anne A. Gershon,MD
• Marc D. Foca, MD
• Philip L. Graham III, MD MSc
• Philip LaRussa, MD
• Natalie M. Neu, MD MPH
• Sameer J. Patel, MD
• Alice Prince, MD
• Adam J. Ratner, MD MPH
• Lisa Saiman, MD MPH

• How to Apply
• Clinical Training
• Research
• Fellowship Program Conferences
• Past and Present Fellows

Marc D. Foca

EDUCATION Johns Hopkins University, BA, 1986 UMDNJ-New Jersey Medical School, MD, 1995 ACADEMIC TITLE Assistant Professor of Pediatrics SPECIALITY HIV Tuberculosis

RESEARCH AND CLINICAL SUMMARY

In addition to my responsibilities as an Infectious Diseases Attending on the hospital consultation service, I am the Medical Director of the Pediatric HIV Clinic at the Morgan Stanley Children's Hospital of New York-Presbyterian (MS CHONY). In this setting, I am responsible for the care of the HIV infected patients and their uninfected siblings that are followed at MS-CHONY. I work in conjunction with two certified nurse practitioners, and I oversee the weekly fellow clinic. We are partially funded by the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) grant. As a result, we have active participation in treatment oriented clinical trials in this population. My own research currently is focused in three areas: 1. Potential toxicities of prenatal antiretroviral exposure in the HIV uninfected newborn, 2. Improved diagnosis and treatment of pediatric tuberculosis with special emphasis on the HIV co-infected patient, and 3. Clinical parameters that could lead to improved care of the HIV infected pediatric patient. Current projects include: a study of mitochondrial to nuclear DNA levels in HIV and antiretroviral exposed but uninfected infants, with a focus on potential toxicities to the developing immune system, proposals for the use of gamma interferon based assays in the diagnosis of latent tuberculosis (LTBI) in HIV infected pediatric patients, and the use of once weekly therapy in the continuation phase of treatment for pulmonary tuberculosis in pediatric patients without HIV. The clinic also is currently looking at changes in lipid levels in patients on their most recent antiretroviral regimen, changes in renal function in perinatally HIV infected patients over time, and the potential for the delayed onset of puberty in perinatally HIV infected adolescent girls. Recently, I have become involved with mentoring pediatric providers participating in the roll out of antiretroviral therapy in both Vietnam and Ethiopia. Potential exists for continued work in both countries as well as additional sites.

OFFICE INFORMATION:

Marc Foca, MD
630 West 168th Street
VC-4 East
New York, NY 10032
Tel: (212) 305-5000
Fax: (212) 342-5218
Email: mdf10@columbia.edu

SELECTED PUBLICATIONS

• Foca M, Jakob K, Whittier S, Della Latta P, Factor S, Rubenstein D, and Saiman L. Endemic Pseudomonas aeruginosa Infection in a Neonatal Intensive Care Unit, N Eng J Med 2000;343:695-700
• Soh C-H, Oleske J, Brady M, Spector S, Borkowsky W, Burchett S, Foca M, Handelsman E, Dankner W, and Hughes M. Long-Term Effects of Combination Antiretroviral Therapy Including Protease Inhibitors on CD4 T Cell Recovery in HIV-1 Infected Children and Adolescents. Lancet 2003; 362: 2045-51
• Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH, McNamara J for the PACTG 1022 Study Team Maternal Toxicity with Continuous Nevirapine in Pregnancy: Results from PACTG 1022. JAIDS, 2004; 36(3): 772-776
• Paul ME, Mao C, Charurat M, Serchuck L, Foca M, Hayani K, Handelsman EL, Diaz C, McIntosh K, and Shearer WT for the Women and Infants Transmission Study (WITS). Predictors of Immunologic Long-Term Nonprogression in HIV Infected Children: Implications for Initiating Therapy. JACI, 2005;115(4):848-55.
• Foca M, Moye J, Chu C, Matthews Y, Rich K, Handelsman E, Luzuriaga K, Leighty R, Paul M, and Diaz C for The Women and Infants' Transmission Study (WITS). Sex Differences in Lymphocyte Populations, Plasma HIV-RNA Copy Number, and Disease Progression in a Cohort of Children Born to Women Infected With The Human Immunodeficiency Virus (HIV). Pediatrics 2006; 118: 146-155.
• Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, Frederick M, Handelsman E, Hayani K, and Shearer WT, for the Women and Infants Transmission Study. The Effect of Perinatal Antiretroviral Drug Exposure on Hematologic and Lymphocytic Blood Values in HIV-Uninfected Children: An Analysis of the Women and Infants Transmission Study. JID, 2006; 194: 1089-97.
• Chantry CJ, Frederick MM, Meyer III WA, Handelsman E, Rich K, Paul ME, Diaz C, Cooper ER, Foca M, Adeniyi-Jones SK, and Moye J. Endocrine Abnormalities and Impaired Growth in HIV-Infected Children. PIDJ 2007; 26: 53-60.
• Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, and Thompson B. Assessment of Birth Defects According to Maternal Therapy among Infants in WITS. JAIDS 2007; 44(3):299-305.
• Patel, SJ, Huard RC, Keller C, and Foca M. Possible Case of CNS Whipple's Disease in an Adolescent with AIDS. J Int Assoc Physicial AIDS Care 2008; 7(2): 69-73.
• Saitoh A, Foca M, Viani RM, Heffernan-Vacca S, Lujan-Zilbermann J, Emmanuel PJ, Deville JG, and Spector SA. Clinical Outcomes in Perinatally Acquired HIV-Infected Children and Adolescents After Unstructured Treatment Interruption. Pediatrics 2008; 121(3): e513-521.